Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand

AIDS

Volumn 12, Issue 12, 1998, Pages 1521-1527

  Churdboonchart, Vina ^a   Moss, Ronald B ^b   Sirawaraporn, Worachart ^a   Smutharaks, Buranaj ^a   Sutthent, Reungpung ^a   Jensen, Fred C ^b   Vacharak, Prawut ^a   Grimes, Janet ^c   Theofan, Georgia ^b   Carlo, Dennis J ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Orchestra Therapeutics Inc   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Asia; CD4; CD8; Therapy; Vaccine

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; THAILAND; TRICEPS BRACHII MUSCLE; VIRUS IMMUNITY; VIRUS LOAD;

ADULT; AIDS VACCINES; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; RNA, VIRAL; THAILAND; TIME FACTORS; TREATMENT OUTCOME; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 15644370351     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199812000-00015     Document Type: Article

References (32)

1. Pear R: New estimate doubles rate of HIV spread. The New York Times, 26 November 1997.
2. Nagachinta T, Duerr A, Suriyanon V, et al.: Risk factors for HIV-1 transmission from HIV-seropositive male blood donors to their regular female partners in Northern Thailand. AIDS 1997, 11:1765-1772.
3. Workshop Report from the European Commission and the Joint United Nations Programme on HIV/AIDS: HIV-1 subtypes: implications for epidemiology, pathogenicity, vaccines and diagnostics. AIDS 1997, 11:UNAIDS17-UNAIDS36.
4. Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, Poiesz BJ: Sequence note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses 1997, 13:357-361.
5. Trauger RJ, Ferre F, Daigle AE, et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type-1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994, 169:1256-1264.
6. Turner JL, Trauger RJ, Daigle AE, Carlo DJ: HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 1994, 8:1429-1435.
7. Moss RB, Trauger RJ, Giermakowska WK, et al.: Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:343-350.
8. Moss RB, Wallace MR, Lanza P, et al.: In vitro p24 antigen stimulated lymphocyte proliferation and β-chemokine production after immunization with an inactivated gp120-depleted HIV-1 immunogen (REMUNE™) in HIV-1 seropositive subjects. Clin Diagn Lab Immunol 1998, 5:308-312.
9. Limsuwan A, Churdboonchart V, Moss RB, et al.: Safety and immunogenicity of REMUNE™ in HIV-infected Thai subjects. Vaccine 1997, 16:142-149.
10. Richieri SP, Bartholomew R, Aloia CR, et al.: Characterization of highly purified inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine 1997, 16:119-129.
11. Revets H, Marissens D, De Wit S, et al.: Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICORE-HIV Monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996, 34:1058-1064.
12. Prior C, Bay P, Ebert B, et al.: Process development for the manufacture of inactivated HIV-1. Pharm Tech 1995, 19:30-52.
13. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
14. Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S: Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 1991, 44:481-493.
15. Pau C-P, Lee-Thomas S, Auwanit W, et al.: Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993, 7:337-340.
16. Delwart EL, Shaper EG, Loawagie J, et al.: Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 1993, 262:1257-1261.
17. Levine AM, Groshen S, Allen J, et al.: Initial studies on active immunization of HIV-1 infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J Acquir Immune Defic Syndr 1996, 11:351-364.
18. Trauger RJ, Ferre F, Daigle AE, et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994, 169:1256-1264.
19. Binley JM, Klasse PJ, Cao Y, et al.: Differential regulation of the antibody responses to gag and env proteins of human immunodeficiency virus type 1. Virology 1997, 71:2799-2809.
20. Moss RB, Giermakowska W, Lanza P, et al.: Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE™) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol 1997, 10:221-228.
21. Moss RB, Ferre F, Trauger R, et al.: Observations on the control of progression of HIV infection following immunization with an inactivated HIV immunogen in IFA. X International Conference on AIDS. Yokohama, August 1994 [abstract RR-1].
22. Mulligan K, Tai VW, Schambelan M: Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:43-48.
23. Schambelan M, Mulligan K, Grunfeld C, et al.: Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med 1996, 125:873-882.
24. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J: An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997, 24:764-774.
25. Young NL, Ponglertnapakorn P, Shaffer N, et al.: Clinical field site evaluation of the FACS count for absolute CD3+, CD3+CD4+, and CD3+CD8+ cell count determinations in Thailand. Clin Diagn Lab Immunol 1997, 4:783-786.
26. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
27. Kalams SA, Buchbinder SP, Billingsley JM, et al.: Coordinate control of HIV replication mediated by CD4 and CD8 cells. Keystone Symposia: HIV Pathogenesis and Treatment. Park City (UT), March 1998 [abstract 4048].
28. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
29. Ferbas J, Plaeger S, Amini S, Hausner M, Detels R, Giorgi JV: In vitro production of RANTES, MIPIα and MIPIβ as a correlate of decreased HIV burden. Conference on Advances in AIDS Vaccine Development: Ninth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS. Bethesda, May 1997 [poster 91].
30. Moss RB, Trauger RJ, Giermakowska WK, et al.: Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:343-350.
31. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
32. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.